Announced Mon, 13 Jul · 17:35 IST
Routine compliance filing for share dematerialisation Q1 FY27
Compliance View source PDF
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+0.1%1-day move
₹2460.00
prior close
₹2461.10
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.2+0.4+0.9+1.6+0.1+3.5-0.4-0.1+1.0-2.9————
Up moveDown movePending
AI summary
Gland Pharma submitted a routine quarterly compliance certificate from its Registrar MUFG Intime India, confirming that all share certificates received for dematerialisation during the quarter ended June 30, 2026 were processed, confirmed or rejected to the depositories, and listed on the stock exchanges within the prescribed timelines. This is a standard SEBI regulatory filing under Regulation 74(5).
Likely market impact
No impact on shareholders. This is a routine quarterly compliance filing with no business or price implications.